Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Q3 FY24 Earnings Presentation
24 slides from Alembic Pharmaceuticals's earnings presentation, Feb 5, 2024
Slide 1: Exchange filing cover letter
Date: 5th February, 2024 To, To, The Manager, The Manager, Department of Corporate Services, Listing Department, BSE Limited National Stock Exchange of India Ltd. P. J. Towers, Dalal Street, ‘Exchange Plaza’, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 53357
Slide 2: Investor Presentation Q3 and YTDFY24
Alembic Pharmaceuticals Limited Investor Presentation Q3 and YTDFY24 Feb 5, 2024
Slide 3: Safe Harbour Statement
Safe Harbour Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diff
Slide 4: Quarterly Snapshot
Quarterly Snapshot INR Bn Key Highlights : 8% YoY India Branded Business : India Branded Business at Revenue R&D INR 5.96 Bn witnessed growth of 9% in Q3FY24 16.31 2% QoQ 7% of Sales against IPM growth of 8%. US Generics : Growth of 9% on YoY basis led by 11 new launches in the quarter and market sh
Slide 5: Revenue Snapshot
Revenue Snapshot INR Bn Business Q3 FY24 Q3 FY23 Y-o-Y Q2FY24 Q-o-Q 9M FY24 9M FY23 Y-o-Y Formulations India 5.96 5.45 9% 5.77 3% 16.97 15.74 8% US 4.74 4.32 9% 4.44 7% 13.08 12.17 7% Ex-US 2.72 2.06 32% 2.52 8% 7.9 6.02 31% API 2.89 3.26 -11% 3.22 -10% 9.17 8.53 8% Total Revenue 16.31 15.09 8% 15.9
Slide 6: India branded business driving growth
India branded business driving growth Revenue - Q3 FY 24 Revenue - 9M FY24 INR Bn CAGR : 11.9% INR Bn 16.97 15.73 Growth: 9% 14.78 5.45 5.96 11.39 10.83 Vet 0.96 0.73 Acute 1.97 2.02 Specialty 2.75 2.98 Q3FY23 Q3FY24 9M FY20 9M FY21 9M FY22 9M FY23 9M FY24 Sales Mix - Q3 FY 24 Anti Infective India
Slide 7: Branded Business – Rx driven rankings
Branded Business – Rx driven rankings Top Brands with Rank and Market Share Driving overall Prescription Business *Figures in Mn Rank MS% Rank MS% BRANDS BRANDS Q3 FY 24* Q3 FY 24 Q3 FY 24* Q3 FY 24 130.5 0.23 48 AZITHRAL 1 33.3 WIKORYL 3 10.5 ALTHROCIN 1 89.2 SHARKOFERROL 3 6.7 MAT Dec 23 ROXID 1 9
Slide 8: High focus therapies outgrowing market
High focus therapies outgrowing market Performed relatively better than the market in Antibiotic and Respiratory segments on high base in previous year corresponding quarter. Gynecology, Gastrointestinal, Anti Diabetic and Ophthalmology outpaced market growth. Q3 FY23-24 Growth Comparison Therap
Slide 9: New Launches
New Launches New launches continue to do well along with promising future launches across key segments. Q3 FY24 Therapy Molecule Brands Launch INR Mn Dydrogesterone ISOFIT 2022 151 Gynecology Iron Ferric RICHAR-FCM 2023 14 ULGERAFT 2022 47 Gastrointestinal Raft Mkt EXCERAFT 2022 11 Vildagliptin + Me
Slide 10: Animal Health Business
Animal Health Business Revenue - Q3 FY24 Revenue - 9M FY24 Growth 32% CAGR 24.1% INR Mn 2740 2190 1795 Q3FY23 1388 Q3FY24 960 1156 730 Q3FY23 Q3FY24 9M FY20 9M FY21 9M FY22 9M FY23 9M FY24 Sales Mix - Q3 FY24 Operating in Livestock and Poultry market Antibiotic 39% Established new division with
Slide 11: Technology transforming business
Technology transforming business Deployment of Ipads for MR interaction with the Healthcare Medical Professional’s (HMP’s) - Upgrading our scope to communicate medico-marketing content to the HMP for our brands along with an increased time spend during calls. Upgraded to SalesForce platform for
Slide 12: US Generics market stabilizing…
US Generics market stabilizing… Revenue- Q3 FY24 Revenue – Last 5 years INR Bn INR Bn 4.74 CAGR - 5% 4.32 Growth 9% 21.63 19.76 16.66 15.72 12.88 Q3FY23 Q3FY24 FY19 FY20 FY21 FY22 FY23 Approved ANDAs Injectable 12 Inhalation Derma 2 Well-established US front end with strong customer base 27 11 pro
Slide 13: …ex-US market showing exceptional growth…
…ex-US market showing exceptional growth… Revenue – Q3 FY24 Revenue – Last 5 years 2.71 INR Bn INR Bn Growth 32% 2.06 CAGR: 15% 8.52 7.79 7.75 Q3FY23 Q3FY24 Recorded 32% growth led by robust demand across markets 4.94 4.97 Ex-US driven by partnership Presence in following key markets - Europe, Ca
Slide 14: …and API market rising steadily
…and API market rising steadily Revenue – Q3 FY24 Revenue – Last 5 years INR Bn INR Bn 3.26 De-Growth 11% 2.89 CAGR: 11% 11.66 9.55 9.39 Q3FY23 Q3FY24 7.71 7.08 Decline of 11% on YoY basis, largely led by low off-take from few selected customers - transitionary in nature. 1 US DMF filed till Dec’2
Slide 15: R&D investments set to decline
R&D investments set to decline Dosage form wise ANDA approval and Launch R&D Capabilities Q3FY24 YTD Dec'23 Dosage Forms Approval Formulation : Vadodara and Hyderabad Launch Approval Launch * OSD 2 3 8 7 API : Vadodara and Hyderabad Injectable - Gen 1 4 3 5 Bio Centre : Vadodara Injectable - Onco 1
Slide 16: Yearly Financials
Yearly Financials Revenue INR Bn EBIDTA Net Profit INR Bn INR Bn 16.31 56.53 11.78 53.93 53.06 46.06 12.13 10.53 # 8.29 7.79 # 6.65 # 4.97 # FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 EBIDTA margin % Capex INR Bn ROCE % 41* 30 26 6.97 6.87 32 * 20 # 4.67 25*# 4.12 14 # 14*# FY20 FY2
Slide 17: Enhancing ESG compliance
Sustainability Enhancing ESG compliance Targets: 19% Reduction in Indirect Energy Consumption 28% Reduction in Water Consumption(KL/MT) 16% Reduction (YoY) in Total GHG Emissions (Scope 1&2)(TCO2) Net-Zero by 2040 21% Reduction in Hazardous Waste (MT/MT of Production) Water Neutrality by 2027 C
Slide 18: Strategic Roadmap
Strategic Roadmap Business Initiatives in FY23 Plan for FY24 • Create new marketing division for increasing • Strengthened the presence in sales volumes from high-growth therapies specialty therapies with the launch of • Introduce Data Analytics into onfield The India Business novel products operati
Slide 19: Company Overview
Company Overview
Slide 20: Company at a Glance
Company at a Glance Mission Prescribers in India Improve healthcare with innovation, commitment and trust 2,30,000 Team size Field Force 14,500 + 5,000 + Brands Manufacturing facilities 9 185 ANDA filings Net Zero 257 (Dec 31, 2023) 2040 R&D Centres Products in US 2 140
Slide 21: Value Proposition
Value Proposition Developing Supplying APIs Ranks 20th in the specialty drug to 60+ countries Indian formulations pipeline for India globally market Exploring Consistent and Established a opportunities in High Dividend presence in Chile Injectables Payout & UAE Strengthening presence Expanding in Ca
Slide 22: The Journey
The Journey 1907 2007 2008 2009 2010 2012 2006 Acquired Dabur’s FDA approved Pharmaceutical Established by FDA approved FDA approved APIIndian Cardiology, facility FDA approved Multiple divisions to business demerged Formed a JV, Amin Family GI and Gynecology Formulation address chronic API facility
Slide 23: Robust Infrastructure
Robust Infrastructure Last USFDA Location Dosage Form Audit International Generics F1 – Panelav General Oral Solids Mar’20 Oncology Oral Solids Jun’19 F2 – Panelav Oncology Injectables Oct’22 F2 - F3 - General Injectables Panelav Karkhadi F3 – Karkhadi Ophthalmic Mar’23 F4 – Jarod General Oral Solid
Slide 24: Thank you
For further queries, please contact: Mr. Ajay Desai ajay.desai@alembic.co.in 022-6695 3999 Mr. Mitanshu Shah mitanshu.shah@alembic.co.in 0265-663 7630 Thank you Investor Relations Advisors : Adfactors PR Pvt. Ltd. Snighter Albuquerque snighter.a@adfactorspr.com Darshan Mankad darshan.mankad@adfactor
Alembic Pharmaceuticals — Q3 FY24 Earnings Presentation on 6ix